SG10202105262QA - St-246 liquid formulations and methods - Google Patents

St-246 liquid formulations and methods

Info

Publication number
SG10202105262QA
SG10202105262QA SG10202105262QA SG10202105262QA SG10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA
Authority
SG
Singapore
Prior art keywords
methods
liquid formulations
formulations
liquid
Prior art date
Application number
SG10202105262QA
Other languages
English (en)
Inventor
Shanthakumar R Tyavanagimatt
Melialani A C L Stone
William C Weimers
Gopi Krishna Kasi
Peter N K Samuel
Tove' C Bolken
Dennis E Hruby
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of SG10202105262QA publication Critical patent/SG10202105262QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
SG10202105262QA 2010-08-05 2011-08-02 St-246 liquid formulations and methods SG10202105262QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37097110P 2010-08-05 2010-08-05
US201161450359P 2011-03-08 2011-03-08

Publications (1)

Publication Number Publication Date
SG10202105262QA true SG10202105262QA (en) 2021-06-29

Family

ID=45559790

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202105262QA SG10202105262QA (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods
SG2013007000A SG187243A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods
SG10201506031UA SG10201506031UA (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2013007000A SG187243A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods
SG10201506031UA SG10201506031UA (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Country Status (15)

Country Link
US (5) US9233097B2 (enrdf_load_stackoverflow)
EP (1) EP2600715B1 (enrdf_load_stackoverflow)
JP (1) JP5898196B2 (enrdf_load_stackoverflow)
KR (1) KR101868117B1 (enrdf_load_stackoverflow)
CN (2) CN103281898A (enrdf_load_stackoverflow)
AR (1) AR082566A1 (enrdf_load_stackoverflow)
AU (1) AU2011285871B8 (enrdf_load_stackoverflow)
BR (1) BR112013002646B1 (enrdf_load_stackoverflow)
CA (1) CA2807528C (enrdf_load_stackoverflow)
DK (1) DK2600715T3 (enrdf_load_stackoverflow)
IL (1) IL224430B (enrdf_load_stackoverflow)
MX (2) MX368106B (enrdf_load_stackoverflow)
SG (3) SG10202105262QA (enrdf_load_stackoverflow)
WO (1) WO2012018810A1 (enrdf_load_stackoverflow)
ZA (1) ZA201300930B (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104414983B (zh) * 2013-08-28 2018-09-04 山东新时代药业有限公司 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺
EP3043793B1 (en) * 2013-11-19 2021-01-06 Siga Technologies Inc. Rehydration of micronized tecovirimat monohydrate
EP3154535A4 (en) * 2014-06-12 2018-02-14 University of Notre Dame du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CN105816422B (zh) * 2015-01-05 2020-08-14 天士力医药集团股份有限公司 一种水飞蓟宾注射剂及其制备方法
CA2981873A1 (en) 2015-04-10 2016-10-13 Bae Systems Plc Long range sensor apparatus and method of providing a long range sensor apparatus
CN107625967B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US12226431B2 (en) * 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CN116211821A (zh) * 2023-02-06 2023-06-06 青岛增益安生物科技有限公司 一种特考韦瑞的药物混合方式
US11903962B1 (en) 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080080A1 (en) 2002-03-21 2003-10-02 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
CA2529761C (en) * 2003-06-20 2013-08-13 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2007351866C1 (en) * 2003-06-20 2013-07-25 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CA2594602A1 (en) * 2004-12-23 2006-06-29 Pfizer Limited 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors
JP2008535862A (ja) * 2005-04-08 2008-09-04 キメリクス,インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
PL2581078T3 (pl) * 2005-10-26 2015-07-31 Cydex Pharmaceuticals Inc Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
US20100056500A1 (en) * 2006-11-21 2010-03-04 Thitiwan Buranachokaisan Stable Parenteral Formulation
ES2438496T3 (es) * 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso

Also Published As

Publication number Publication date
SG187243A1 (en) 2013-02-28
BR112013002646A2 (enrdf_load_stackoverflow) 2013-02-04
US10576165B2 (en) 2020-03-03
JP5898196B2 (ja) 2016-04-13
WO2012018810A1 (en) 2012-02-09
US9907859B2 (en) 2018-03-06
AU2011285871A1 (en) 2013-02-21
KR20130135836A (ko) 2013-12-11
JP2013532729A (ja) 2013-08-19
AU2011285871B8 (en) 2015-05-14
US20180185514A1 (en) 2018-07-05
CA2807528A1 (en) 2012-02-09
AU2011285871A8 (en) 2015-05-14
KR101868117B1 (ko) 2018-06-18
US9233097B2 (en) 2016-01-12
CN106074370A (zh) 2016-11-09
US10124071B2 (en) 2018-11-13
US20160082128A1 (en) 2016-03-24
AR082566A1 (es) 2012-12-19
US20200138974A1 (en) 2020-05-07
CA2807528C (en) 2018-09-25
CN103281898A (zh) 2013-09-04
SG10201506031UA (en) 2015-09-29
EP2600715B1 (en) 2019-12-11
ZA201300930B (en) 2015-11-25
BR112013002646B1 (pt) 2022-01-04
US10864282B2 (en) 2020-12-15
EP2600715A1 (en) 2013-06-12
WO2012018810A9 (en) 2012-04-05
EP2600715A4 (en) 2016-04-20
US20140011854A1 (en) 2014-01-09
IL224430B (en) 2019-09-26
US20190038767A1 (en) 2019-02-07
AU2011285871B2 (en) 2015-04-23
MX2013001389A (es) 2013-06-07
MX347795B (es) 2017-05-12
DK2600715T3 (da) 2020-03-16
MX368106B (es) 2019-09-19

Similar Documents

Publication Publication Date Title
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
ZA201300930B (en) St-246 liquid formulations and methods
PT2539326T (pt) Ariltriazolonas ligadas a bisaril e sua utilização
IL220939A0 (en) Compounds and methods
GB2481881B (en) Liquid formulations
EP2523664A4 (en) COMPOUNDS AND METHODS
ZA201208173B (en) Peptices and their use
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
PT3650125T (pt) Atomizador de líquidos e métodos
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
IL220812A0 (en) Compounds and methods
AP2013006947A0 (en) Compounds and their use
EP2523560A4 (en) CONNECTIONS AND METHODS
PL2521445T3 (pl) Preparat i jego zastosowanie
GB201018650D0 (en) Methods and compositions
GB201008286D0 (en) Device and use
GB201013871D0 (en) Liquid formulations
GB201008873D0 (en) Liquid formulations
TWM385891U (en) Thermo-pressing and thermo-cutting device
GB201010083D0 (en) Compositions and methods
GB201018651D0 (en) Methods and compositions
GB201009767D0 (en) Compositions and methods
GB201001384D0 (en) Light-fitting and associated methods
GB201003741D0 (en) Methods and therapeutic compositions
GB201113314D0 (en) Formulations and processes